SCHEMBL7101629

SCHEMBL7101629

C=C(c1cccc([N+](=O)[O-])c1)c1c[nH]cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.49
▸ CES1 P23141 1/20 0.49
▸ TP53 P04637 1/20 0.48
▸ ALDH1A1 P00352 6/20 0.47
▸ TSHR P16473 4/20 0.47
▸ PRSS1 P07477 1/20 0.44
▸ PRSS2 P07478 1/20 0.44
▸ PRSS3 P35030 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ LMNA P02545 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14880709 0.79 CES2 (0.69) CES2CES1TP53ALDH1A1TSHR
SCHEMBL16395918 0.75 TP53 (0.66) CES2CES1TP53ALDH1A1TSHR
SCHEMBL9302540 0.73 CES2 (0.49) CES2CES1TP53ALDH1A1TSHR
SCHEMBL5269547 0.70 IDO1 (0.56) ALDH1A1TSHRLMNAMAPTNPC1
SCHEMBL27983482 0.70 ALDH1A1 (0.71) CES2CES1TP53ALDH1A1TSHR
SCHEMBL27871499 0.70 CES2 (0.65) CES2CES1TP53ALDH1A1TSHR
SCHEMBL9452381 0.70 ALDH1A1 (0.71) CES2CES1TP53ALDH1A1TSHR
SCHEMBL9023714 0.69 IRAK4 (0.47) CES2CES1TP53ALDH1A1TSHR
SCHEMBL4092998 0.69 CES2 (0.74) CES2CES1TP53ALDH1A1TSHR
SCHEMBL7984018 0.69 FLT1 (0.53) CES2CES1TP53ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 — — US disclosed
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 — — EP disclosed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A CES2 274/4885CES1 101/4885TP53 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback